Somapacitan Is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: A Randomized Controlled Phase 3 Study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as young children, children and teenagers, both men and women.

Annualized height velocity (HV; cm/year) at week 52 was the primary measurement.

Additional assessments included HV standard deviation score (SDS), height SDS (HSDS), bone age, insulin-like growth factor-I (IGF-I) SDS, and observer-reported outcomes.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

Groups ran in parallel: each of the participants stayed in one arm throughout.

What Was Measured

The subject headings attached to it are Human Growth Hormone, Insulin-Like Growth Factor I, Body Height, China, Dwarfism, Pituitary and East Asian People.

The authors tagged it with the keywords Growth hormone deficiency, Growth hormone replacement therapy, Long-acting growth hormone and Somapacitan.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.